Loading...

IDYA IDEAYA BIOSCIENCES INC Expansion Plans 8-K Filing

DY B

DY

IDEAYA BIOSCIENCES INC

(IDYA)

2026 8-K

New Registration Statement

Financial Results Announced

Clinical Trial Update

Clinical Collaboration Agre...

Financial Results Report

Business Update

Corporate Presentation Update

Collaboration Termination

GSK Termination Notice

Quarterly Earnings Report

Positive Clinical Results

License Agreement Signed

Financial Statements

Financial Results

Management Change

License Agreement

Q3 Financial Results

Clinical Update

Presentation Announcement

Clinical Trial Update

Financial Results Announcement

Agreement with Biocytogen P...

Underwriting Agreement

Financial Update

Clinical Update

Resignation of Officer

Clinical Updates

Annual Meeting of Stockholders

Financial Results Announcement

Agreement with MSD Internat...

Financial Results Announcement

Open Market Sales Agreement

Collaboration Agreement

Lease Agreement

Earnings Reports

Underwriting Agreement

Financial Update

Clinical Updates

Resignation of CFO

Earnings Report

Open Market Sales Agreement

Annual Meeting and Compensa...

Lease Agreement for New Fac...

Amendment to Clinical Trial...

Financial Results Announcement

Underwriting Agreement

Financial Update

Clinical Updates

Financial Results Announcement

External Links:

IDEAYA Biosciences, Inc. reported on January 11, 2026, key objectives for 2026, including advancing four clinical trials for its drugs darovasertib and IDE849, with a projected cash reserve of approximately $1.1 billion to fund operations through 2030.

AI Assistant

IDEAYA BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.